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Abstract. While hepatic arterial chemoembolization is
efficacious for a number of malignancies, there is scant data
regarding treatment of pancreatic adenocarcinoma. We report
a complete radiographic response at one year from diagnosis
of metastatic pancreatic carcinoma. Gemcitabine/cisplatin
based chemoembolization may be of potential benefit for
patients with liver-dominant metastases from pancreatic
carcinoma. Given the typical survival of 6 months or less in
this patient group with standard therapies, further research
is warranted.
Introduction
Pancreatic adenocarcinoma is the 4th most common cause
of cancer death in the United States with 37,700 new
diagnoses and 34,300 deaths projected for 2008 (1).
Outcomes following margin negative resection have
improved over the last decade with 5-year survival ranging
from 7-24% (2). However, metastatic disease to the liver is a
premortal condition. Median survival with metastatic
pancreatic cancer is 4-6 months. Even with newer agents,
such as gemcitabine and erlotinib, survival for metastatic
cancer from the pancreas has not appreciably improved over
the last decade. Pancreatic metastases typically spread
hematologically or via regional lymphatics to the liver and
lung. Transarterial therapies such as chemoembolization,
embolization and radioembolization with 90Y have
demonstrated substantial improval in survival and symptoms
when used to treat unresectable hepatic disease either
originating in the liver or metastasizing to the liver (3).
However, transarterial therapy of liver dominant metastatic
pancreatic carcinoma has not been extensively evaluated.
We report a complete radiographic response in a patient
with liver isolated metastases from pancreatic carcinoma
one year following initiation of therapy with a review of the
relevant literature.
Case report
This type of review does not require approval by our
institution's IRB. This 56-year old male was diagnosed
with a 4-cm mass in the pancreatic tail. The initial metastatic
workup included MR, CT, and PET scans. This revealed no
evidence of metastatic disease (Fig. 1A). The tumor focally
invaded the splenic hilum and the splenic vein was throm-
bosed. His pre-operative CA 19-9 was 209 U/ml (normal
<36 U/ml). The patient underwent a distal pancreatectomy
and en bloc splenectomy in July 2008 and made an uncom-
plicated recovery. Pathology revealed a grade III poorly
differentiated 4.0x3.0-cm ductal adenocarcinoma with signet
ring features (Fig. 1B). The final report noted that the tumor
contained synchronous pancreatic intraepithelial neoplasia
with the highest grade being PanIN 2. Eight lymph nodes
were resected and all were free of disease. The margins of
the surgical specimen were uninvolved by tumor. The patient
recovered uneventfully and was discharged home.
Follow-up CT in September 2008 demonstrated a
2.4x2.8-cm mass in the anterior segment of the right hepatic
lobe (Fig. 1C). Sonographically guided fine needle aspiration
confirmed the diagnosis of metastatic adenocarcinoma. He
was referred for chemoembolization. Thermal ablation for
this mass was considered but not performed given the concern
that other hepatic micrometastases were likely present. In
September 2008 after obtaining informed consent, the patient
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underwent chemoembolization with gemcitabine 1,000 mg/m2
and cisplatin 100 mg/m2. The patient was pre-medicated with
anti-emetics, steroids, diuretics, and sodium thiosulfate. The
right hepatic artery was selected with a micro-catheter.
Following infusion of the chemotherapeutic agents,
embolization to near stasis was performed with a gelfoam
slurry. He was hydrated overnight (including continued
thiosulfate) and discharged the following morning.
At repeat imaging, the mass was similar in size albeit less
well-defined. The patient underwent similar weight based
chemoembolization again in November, 2008 after which
a partial response using Response Evaluation Criteria in
Solid Tumors (RECIST) criteria was identified. The patient
underwent 2 more similar sessions in January and March,
2009. Follow-up MRI in June, 2009 did not demonstrate any
evidence of malignancy (Fig. 1D). Given that the patient's
primary tumor was metabolically active prior to resection,
CT/PET was repeated. No hypermetabolic foci were present
(Fig. 1E).
Discussion
Shibata et al reviewed outcomes of patients with recurrent
disease following attempted curative resection of pancreatic
carcinoma (4). Multivariate analysis found that patients with
poorly differentiated tumors had a significantly greater risk
of developing liver metastases (p=0.014, Odds Ratio of
7.432). Patients with hepatic metastases had a mean survival
of 13 months and a 0% 5-year survival. Gemcitabine is the
cornerstone of therapy for metastatic pancreatic carcinoma
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Figure 1. A 57-year old male with pancreatic carcinoma. (A) CT scan prior
to Whipple procedure demonstrates a pancreatic tail mass which involves
the splenic hilum. (B). Hematoxylin and eosin stain (magnification x200)
demonstrates an area of the tumor with a mucin containing signet ring cell
(arrow) and surround infiltrative tumor stroma. (C). Contrast-enhanced
CT scan two months following surgery demonstrates a hypovascular mass
in segment VIII. (D) Following 4 sessions of cisplatin/gemcitabine based
chemoembolization, there is a complete radiographic response. (E) PET/CT
fusion imaging does not reveal any hypermetabolic focus in the treated area
of the liver.
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based on a previous randomized trial where patients survived
a median of 5.65 months with 18% surviving one year (5).
Since that trial, a number of studies have been performed in
an attempt to find a combination with gemcitabine to further
extend survival without success. Most recently, 832 patients
enrolled in a phase III trial studying gemcitabine 1,000 mg/m2
given over 30 min versus gemcitabine 1,500 mg/m2 given
over 150 min versus combination gemcitabine 1,000 mg/
m2/100 min and oxaliplatin 100 mg/m2 on consecutive days
(1). Simple 30-min infusions of gemcitabine were superior
to either higher doses or the addition of a second agent.
The authors noted that other phase III trials evaluating the
combination gemcitabine with biologic agents such as
bevacizumab or cetuximab have similarly had disappointing
results.
Cisplatin has been used as a combination agent with gem-
citabine in a phase II trial for metastatic pancreatic carcinoma
(6). Patients in this study received gemcitabine 1,000 mg/m2
over 30 min on days 1, 8, and 15 of each cycle and cisplatin
75 mg/m2 following the first drug on day 1. Although this
treatment regimen requires validation by performance of a
phase III study, median survival in this 52 patient group
was 11.8 months and 50% remained alive at 12 months.
Based on this study, exploration of gemcitabine and cisplatin
infusion/embolization for patients with liver dominant
pancreatic carcinoma could have merit to maximize drug
delivery. Investigation is particularly of value in light of the
abysmal survival in this patient group with standard systemic
therapy.
There are few reports of arterial chemoinfusion or
embolization to treat hepatic metastases from pancreatic
carcinoma. Most have involved infusions lasting several days.
Furuse et al performed 5-day infusions of 5-fluorouracil
(5-FU) 500 mg/m2/day every 4 weeks in 13 patients (7). One
patient (8%) demonstrated a partial response. The prolonged
infusions of 5-FU resulted in hepatic arterial occlusion in 3
patients. While no grade III or IV toxicities occurred, median
survival was only 15.9 weeks. Ishii et al investigated the
combination of weekly 5-FU 1,000 mg/m2 over 5 h plus 50 Gy
external beam radiation to the unresected pancreatic malig-
nancy (2 Gy in 25 fractions) (8). Thirteen patients received
a median of 13 cycles of chemotherapy. Seven (41%) of
the patients demonstrated a partial response. Four patients
developed duodenal ulcers and 2 patients developed grade
III or greater toxicity. The median overall survival was 4.5
months with a 1-year survival of 11.8%. The final study in
the English language reported on attempted neoadjuvant
arterial infusion with intra-arterial infusion of cisplatin at
10 mg/m2/day and 5-FU at 500 mg/m2/day (9). After 14 days
of infusion, the patient developed a vasculopathy preventing
further intra-arterial therapy. One potential advantage in
the technique described in our patient is the relatively short
infusion times. With aggressive hydration and treatment
with antiemetics and thiosulfate, he was able to be
discharged the day following each procedure. Over 4 intra-
arterial infusions, our patient had no reportable toxicity
using the Common Terminology Criteria for Adverse
Events, version 3 (CTCAE v3). 
While the outcome in this patient is promising, enthu-
siasm for this outcome needs to be tempered by the limited
experience in other patients. However, the response to
therapy along with the absence of toxicity suggests that there
may be a role for catheter directed intra-arterial therapy for
patients with liver dominant metastases from pancreatic
carcinoma. Given the poor outcomes with standard therapies
in this patient group, further investigation of catheter directed
therapy in appropriate patients should be performed.
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